Retour aux projets

18282.2 PFLS-LS

Development of a theranostic agent for imaging and treatment of neuroendocrine tumours, using Positron|Emission Tomography and Peptide Receptor Radionuclide Therapy, based on a new generation of|radiolabelled somatostatin analogues

Résumé

Development of a theranostic agent for imaging and treatment of neuroendocrine tumours, using Positron|Emission Tomography and Peptide Receptor Radionuclide Therapy, based on a new generation of|radiolabelled somatostatin analogues

Textes supplémentaires

Abstract

The project targets the development of the novel somatostatin (SST) analogue G02113, with high affinity to|the SST receptor subtypes 2 and 5, as a theranostic agent for the management of patients suffering|from neuroendocrine tumours (NETs). G02113 labelled with 68Ga will be developed as a Positron Emission|Tomography (PET) imaging tracer for diagnostic imaging and therapy follow-up of NETs, while the same|compound labelled with 177Lu will be developed as a therapeutic agent for Peptide Receptor Radionuclide|Therapy (PRRT).

Participants

Alan Harris

Wirtschaftspartner

SomTheranostics Sàrl Alan Harris Chemin de Beaufort 12 1162 St-Prex VD CH

Melpomeni Fani

Kontaktperson

Melpomeni.Fani@usb.ch

Universitätsspital Basel Melpomeni Fani Petersgraben 4 4031 Basel BS CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2016-03-31
Date de fin
2018-04-30
Coûts totaux approuvés
CHF 276336.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T115 Medical technology 100.0%